- Home
- UWMC vs PHVS Comparison
UWMC vs PHVS Comparison
Compare UWMC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- PHVS
- Stock Information
- Founded
- UWMC 1986
- PHVS 2015
- Country
- UWMC United States
- PHVS Switzerland
- Employees
- UWMC N/A
- PHVS N/A
- Industry
- UWMC Finance: Consumer Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- PHVS Health Care
- Exchange
- UWMC Nasdaq
- PHVS Nasdaq
- Market Cap
- UWMC 825.8M
- PHVS 980.3M
- IPO Year
- UWMC N/A
- PHVS 2021
- Fundamental
- Price
- UWMC $4.25
- PHVS $17.92
- Analyst Decision
- UWMC Buy
- PHVS Buy
- Analyst Count
- UWMC 8
- PHVS 6
- Target Price
- UWMC $6.46
- PHVS $37.17
- AVG Volume (30 Days)
- UWMC 7.4M
- PHVS 29.1K
- Earning Date
- UWMC 08-05-2025
- PHVS 08-13-2025
- Dividend Yield
- UWMC 9.64%
- PHVS N/A
- EPS Growth
- UWMC N/A
- PHVS N/A
- EPS
- UWMC N/A
- PHVS N/A
- Revenue
- UWMC $2,486,541,000.00
- PHVS N/A
- Revenue This Year
- UWMC $11.32
- PHVS N/A
- Revenue Next Year
- UWMC $22.84
- PHVS N/A
- P/E Ratio
- UWMC N/A
- PHVS N/A
- Revenue Growth
- UWMC 10.39
- PHVS N/A
- 52 Week Low
- UWMC $3.80
- PHVS $11.51
- 52 Week High
- UWMC $9.74
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- UWMC 52.67
- PHVS 55.94
- Support Level
- UWMC $3.98
- PHVS $17.05
- Resistance Level
- UWMC $4.40
- PHVS $19.00
- Average True Range (ATR)
- UWMC 0.16
- PHVS 1.00
- MACD
- UWMC 0.01
- PHVS 0.05
- Stochastic Oscillator
- UWMC 79.34
- PHVS 70.17
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.